Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
WALTHAM, Mass., Dec. 18, 2017 -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it has been added to the Russell 2000® Index, as part of Russell’s quarterly IPO additions, effective Friday, December 15, 2017, after market close.
The Russell 2000® Index, a subset of the Russell 3000® Index, measures the performance of the small-cap segment of the U.S. equity market. The Russell 2000® Index includes approximately 2,000 of the smallest securities based on a combination of their market cap and current index membership.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. These investigational therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, such as macrophages. We have used our platform to develop a diverse pipeline of tumor-targeted and immuno-targeted drug candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their responses to treatment.
Contacts:
Media:
Gina Nugent, The Yates Network
[email protected]
617-460-3579
Investor Relations:
Laura Perry or Sam Martin, Argot Partners
[email protected] or [email protected]
212-600-1902
Company:
Christopher J. Morl, Chief Business Officer
Deciphera Pharmaceuticals, Inc.
[email protected]
781-209-6418
